21 October 2016

Avacta Group plc

('Avacta', 'the Group' or 'the Company')

Director's Dealing

Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics, research and diagnostic reagents, announces that Dr.Mike Owen, a Non-Executive Director of the Group, has purchased today 7,763 Ordinary Shares of 10p each in the Group at a price of 90.0 pence per share.

Following this transaction, Dr Owen's total interest in the Group is 7,763 Ordinary Shares of 10p each, representing less than 0.1% of Avacta's issued share capital.

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.

Enquiries:

Avacta Group plc

Alastair Smith, Chief Executive Officer

Tony Gardiner, Chief Financial Officer

Tel: +44 (0) 844 414 0452

www.avacta.com

finnCap Ltd

Geoff Nash / Giles Rolls - Nominated Adviser

Tim Redfern / Alice Lane - Corporate Broking

WG Partners

David Wilson

Nigel Barnes

Claes Spang

Tel: +44 (0) 207 220 0500

www.finncap.com

Tel: +44 (0) 203 705 9318

Tel: +44 (0) 203 705 9217

www.wgpartners.co.uk

Media Enquiries

FTI Consulting

Simon Conway / Natalie Garland-Collins

Tel: +44 (0) 203 727 1000

avacta@fticonsulting.com

Notes to Editors

Avacta Group plc(www.avacta.com)

Avacta's principal focus is on its proprietary Affimer technology which is anovel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.

Antibodies dominate markets worth in excess of $75bn despite their shortcomings. Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer technology isbased on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of targets to enable diagnostics, research assays and therapeutics.

Avacta has a pre-clinical therapeutic development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1.

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Dr Mike Owen

2.

Reason for the Notification

a)

Position/status

Non - Executive Director

b)

Initial notification/Amendment

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Avacta Group Plc

b)

LEI

n/a

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Identification code

GB00BYYW9G87

b)

Nature of the transaction

Purchase of 10p Ordinary Shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

90.0 pence

7,763

d)

Aggregated information:

· Aggregated volume

· Price

See above

e)

Date of the transaction

21 October 2016

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

Avacta Group plc published this content on 21 October 2016 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 21 October 2016 10:43:02 UTC.

Original documenthttp://irservices.netbuilder.com/ir/avacta/newsArticle.php?id=1960284&ST=AVCT

Public permalinkhttp://www.publicnow.com/view/D56CE5C22361D4DE4642B0F03F6B6D643AD7DDE0